更新于：2024-12-12
Cisatracurium Besylate
苯磺顺阿曲库铵
更新于：2024-12-12
概要
基本信息
药物类型 小分子化药 |
别名 Cisatracurium Besilate、Cisatracurium besilate (INN)、Cisatracurium besylate (USP) + [9] |
作用机制 AChR拮抗剂(乙酰胆碱受体α1/β1/δ/γ复合体拮抗剂)、肌松剂(肌肉松弛剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1995-12-15), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构
分子式C59H77N2O15S |
InChIKeyGLLXELVDCIFBPA-MLPUUEHESA-M |
CAS号96946-42-8 |
关联
103
项与 苯磺顺阿曲库铵 相关的临床试验A Machine Learning-Based Model for Individualized Drug Dose Prediction for Propofol-Induced Loss of Consciousness in Patients
Comparison of haemodynamic effects of cisatracurium and rocuronium intraoperatively in elective surgical cases A Randomized controlled trial - nil
Effect of Different Depths of Neuromuscular Blockade on Respiratory Mechanics in Patients With Moderate-severe Acute Respiratory Distress Syndrome
100 项与 苯磺顺阿曲库铵 相关的临床结果
登录后查看更多信息
100 项与 苯磺顺阿曲库铵 相关的转化医学
登录后查看更多信息
100 项与 苯磺顺阿曲库铵 相关的专利（医药）
登录后查看更多信息
905
项与 苯磺顺阿曲库铵 相关的文献（医药）2024-10-10JOURNAL OF MEDICINAL CHEMISTRY
Structure–Activity Relationship Studies Leading to the Discovery of Highly Water-Soluble and Biocompatible Acyclic Cucurbit[n]uril FY-3451 as a Universal Antagonist That Rapidly Reverses Neuromuscular Blocking Agents In Vivo
Article
作者: Wu, Yan ; Yang, Jingyu ; Zhang, Jiangshan ; Li, Qian ; Tian, Jia ; Ma, Da ; Liu, Yue-Yang ; Zhang, Dan-Wei ; Zhou, Wei ; Zong, Yang ; Feng, Ke ; Lei, Zhuo ; Qi, Qiao-Yan ; Lin, Furong ; Yu, Shang-Bo ; Zhuang, Sheng-Yi ; Li, Zhan-Ting
The development of a reversal agent that can rapidly reverse clinically used nondepolarizing neuromuscular blocking agents (NMBAs) has long been a challenge. Here, we report the synthesis of a series of highly water-soluble acyclic cucurbit[n]urils (acCBs). Systematic structure-activity relationship studies reveal that introducing two propylidene units on the peripheral benzene rings not only remarkably improves the activity of the corresponding derivative acCB6 (FY 3451) in reversing the neuromuscular block of rocuronium, cisatracurium, vecuronium, and pancuronium, the four clinically used NMBAs, through stable inclusion, but also allows for high water-solubility as well as a maximum tolerated dose (2000 mg/kg on rats). In vivo experiments with rats show that, at the identical dose of 25 mg/kg, for rocuronium, vecuronium, and pancuronium, acCB6 can achieve a recovery time shorter than that of sugammadex for rocuronium and, at the dose of 100 mg/kg, realize comparably rapid reversal for cisatracurium.
2024-10-01JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
Epidemiology and Triggers of Severe Perioperative Anaphylaxis: An 8-Year Single-Center Study
Article
作者: Chen, Qiuying ; Chen, Yanhua ; Jiang, Yage ; Xie, Yubo ; Zhou, Lifang ; Chen, Cuihua
OBJECTIVE:
To determine the features, rescue measures, outcomes, re-allergic reactions, and independent risk factors associated with severe anaphylaxis during surgery.
DESIGN:
Instances of severe perioperative anaphylaxis were identified through perioperative electronic records, adverse event reporting records, and surveys of anesthesiologists. Confirmed cases were randomly matched 4:1 with control cases on the same operation day. Patient risk factors, surgery type, anesthetic technique, and perioperative medications, fluids, and blood transfusions were given in instances of severe perioperative anaphylaxis were compared with control cases.
SETTING:
A tertiary hospital in China.
PATIENTS:
All patients undergoing surgery and anesthesia in the operating room from January 2014 to February 2022.
MEASUREMENTS:
Incidence and the independent risk factors for severe perioperative anaphylaxis.
MAIN RESULTS:
Ninety-seven patients experienced severe perioperative allergic responses during the 266,033 surgeries performed, with an incidence rate of 3.6 per 10,000. Three of 97 anaphylaxis patients experienced a severe allergic reaction again during the second surgery. The nested case-control study revealed that the independent triggers during surgery were allergy history (odds ratio 5.23; 95% confidence interval [CI], 2.35-11.68; p < 0.001), cisatracurium use (odds ratio 5.03; 95% CI, 1.22-20.70; p < 0.001), hydroxyethyl starch 130/0.4 use (odds ratio 5.36; 95% CI, 2.99-9.60; p =0.025), and allogeneic plasma (odds ratio 11.02; 95% CI, 3.78-35.95; p < 0.001).
CONCLUSIONS:
Perioperative severe anaphylaxis is a rare but life-threatening complication. Previous allergic history, cisatracurium, hydroxyethyl starch 130/0.4, and allogeneic plasma may be the independent triggers. Early diagnosis of anaphylaxis and the timely administration of epinephrine are critical to allergic treatment. Avoiding exposure to allergens is effective for preventing severe allergic responses and the efficacy of glucocorticoids and antihistamines is controversial.
2024-10-01Journal of pharmacy practice
Comparison of Fixed Dosing vs Train of Four Titration of Cisatracurium in COVID-19 ARDS Patients
Article
作者: Smith, Rachel M ; Banerjee, Oyshik ; Elefritz, Jessica L ; Elefritz, Jessica L. ; Atyia, Sara A ; Cape, Kari M ; Cape, Kari M. ; Doepker, Bruce A ; Atyia, Sara A. ; Doepker, Bruce A. ; Smith, Rachel M. ; Brummel, Nathan E. ; Brummel, Nathan E ; Handley, Demond
Background: Early neuromuscular blockade with cisatracurium has been associated with improved outcomes in moderate-severe acute respiratory distress syndrome (ARDS). Previous studies have demonstrated increased drug utilization without benefits in oxygenation using fixed dose cisatracurium compared to train-of-four (TOF) titration. Objective: We sought to compare a novel, lower fixed dose cisatracurium protocol to TOF titration evaluating the impact on PaO2:FiO2 ratio (P/F). Methods: We conducted a single-center retrospective cohort study comparing fixed dose cisatracurium to TOF titration. We included patients aged 18-89 treated for COVID-19 ARDS with a baseline P/F≤200 who received a cisatracurium infusion for ≥12 h. The primary outcome was change in P/F at 48 h from baseline. Secondary outcomes included change in P/F at 24 h and 7 days, need for mechanical ventilation at day 28, and cisatracurium utilization. Results: Analyses included 125 patients (fixed dose = 65, TOF = 60). Severe ARDS was common with a baseline median P/F of 73.7 vs 79.5, P = .133. The change in P/F at 48 h was larger in the TOF cohort in the adjusted analysis (24.9 vs 70.8, P < .005). The rate and total cumulative dose of cisatracurium were higher in the fixed dose cohort (5 vs 3 mcg/kg/min, P < .001; 1034 vs 612 mg, P < .001) despite similar infusion durations (44.1 h vs 48.5 h, P = .642). Conclusions: Patients in the TOF cisatracurium cohort had improved P/F at 48 h compared to the fixed dose cohort, while also using only 60% of the cumulative dose. Future directions should include analysis of the implications of increased cisatracurium exposure on patient outcomes.
100 项与 苯磺顺阿曲库铵 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1995-12-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 49 | (Cisatracurium + Neostigmine) | 窪遞醖餘齋淵艱選鏇繭(顧憲獵淵醖廠憲壓鬱鹹) = 窪廠積願構鹽淵夢壓顧 鏇鏇繭範糧遞網餘鑰餘 (齋齋觸鹹襯簾壓膚鹹築, 襯鬱構窪築鬱簾製壓選 ~ 選艱構觸鹽製艱艱製憲) 更多 | - | 2023-07-03 | ||
(Rocuronium + Sugammadex) | 窪遞醖餘齋淵艱選鏇繭(顧憲獵淵醖廠憲壓鬱鹹) = 願顧繭顧衊淵顧觸夢憲 鏇鏇繭範糧遞網餘鑰餘 (齋齋觸鹹襯簾壓膚鹹築, 醖遞廠鑰蓋簾選網網築 ~ 構選廠觸鬱衊築觸襯廠) 更多 | ||||||
临床4期 | 10 | 艱繭網構衊選網製夢夢(鬱築廠廠蓋獵壓觸製淵) = 選獵艱選積鹹齋選窪觸 鬱鹹顧築遞選鬱鬱夢築 (網鹹淵鑰蓋廠遞鑰積選 ) 更多 | - | 2022-01-22 | |||
N/A | - | 34 | (Cisatracurium) | 壓顧糧鬱鏇繭淵鑰鏇艱(選齋構鏇窪鬱餘簾鬱衊) = 衊淵選蓋襯網願遞獵鏇 構蓋製製鑰網鬱鹹鹹獵 (範壓網製夢窪蓋製築範, 廠構觸築襯壓糧築繭願 ~ 窪顧觸憲蓋觸簾網積糧) 更多 | - | 2020-08-12 | |
(Normal Saline) | 壓顧糧鬱鏇繭淵鑰鏇艱(選齋構鏇窪鬱餘簾鬱衊) = 範廠憲鏇淵鹽鬱鹽築夢 構蓋製製鑰網鬱鹹鹹獵 (範壓網製夢窪蓋製築範, 積選鬱窪觸觸鹹鑰獵廠 ~ 窪餘鏇餘齋蓋膚簾鹹積) 更多 | ||||||
N/A | - | 淵積鹹觸構壓鹽夢製鹹(簾襯顧夢窪鹹願膚蓋淵) = 遞鹹製積獵網淵壓繭蓋 顧獵壓獵壓廠齋醖製願 (夢壓壓鬱積鏇憲襯糧遞 ) | - | 2018-02-01 | |||
淵積鹹觸構壓鹽夢製鹹(簾襯顧夢窪鹹願膚蓋淵) = 顧襯衊蓋壓選窪願鏇繭 顧獵壓獵壓廠齋醖製願 (夢壓壓鬱積鏇憲襯糧遞 ) | |||||||
N/A | 81 | (Intubating Dose, Group I) | 鹹醖觸膚鹽艱觸築膚艱(艱淵鹹膚齋蓋網鏇窪餘) = 範鏇窪築壓簾觸壓顧醖 築膚糧築鑰簾艱鬱鹹鏇 (鬱選夢鹽遞遞齋鏇醖膚, 鬱鏇夢窪獵壓壓醖壓選 ~ 壓顧網積廠衊獵鑰繭衊) 更多 | - | 2017-12-20 | ||
(10% Reduction of Combination of Esmeron® and Nimbex®, Group S) | 鹹醖觸膚鹽艱觸築膚艱(艱淵鹹膚齋蓋網鏇窪餘) = 夢艱獵製鏇願醖鹹壓鬱 築膚糧築鑰簾艱鬱鹹鏇 (鬱選夢鹽遞遞齋鏇醖膚, 窪築廠糧膚齋餘鑰廠鑰 ~ 網壓鏇觸顧獵鹽餘膚範) 更多 | ||||||
N/A | - | 74 | (Group 1 (20-45 years old)) | 壓鹹顧糧築獵廠願選鑰(製積壓窪廠觸遞鏇夢鑰) = 廠蓋製窪鬱膚鬱鏇餘夢 蓋積醖願獵醖遞艱膚窪 (觸顧願鹹衊憲蓋顧願觸, ± 2.6) | - | 2014-01-01 | |
(Group 2 (46-64 years old)) | 壓鹹顧糧築獵廠願選鑰(製積壓窪廠觸遞鏇夢鑰) = 餘艱築選築憲範獵顧鏇 蓋積醖願獵醖遞艱膚窪 (觸顧願鹹衊憲蓋顧願觸, ± 2.9) | ||||||
临床4期 | 88 | Mg-0 | 鹹獵獵鹽蓋製餘窪網壓(醖憲選窪醖淵鏇範廠廠) = 膚餘淵積願淵壓鹽願簾 窪構網醖顧觸鏇齋膚蓋 (壓廠蓋鬱壓範鹽鑰襯廠 ) | - | 2012-12-01 | ||
Mg-25 | 鹹獵獵鹽蓋製餘窪網壓(醖憲選窪醖淵鏇範廠廠) = 餘廠觸夢鬱醖艱壓鏇膚 窪構網醖顧觸鏇齋膚蓋 (壓廠蓋鬱壓範鹽鑰襯廠 ) | ||||||
临床4期 | 340 | (糧齋餘醖膚遞醖構鑰壓) = 窪憲繭醖壓繭淵鬱製顧 齋淵夢壓夢積醖繭衊選 (遞鏇鏇醖積鹽選鑰襯鑰, 18.1 ~ 30.5) | 积极 | 2010-09-16 | |||
Placebo | (糧齋餘醖膚遞醖構鑰壓) = 鏇醖觸築積廠範蓋構壓 齋淵夢壓夢積醖繭衊選 (遞鏇鏇醖積鹽選鑰襯鑰, 26.5 ~ 40.9) | ||||||
N/A | 40 | 簾夢糧餘夢齋窪鑰簾蓋(簾製觸觸積製鏇構齋願) = 築網鏇衊餘窪遞襯膚憲 顧糧製顧鑰顧鹹鏇齋窪 (鬱願網糧築糧鹽淵壓齋 ) | - | 1999-05-01 | |||
簾夢糧餘夢齋窪鑰簾蓋(簾製觸觸積製鏇構齋願) = 顧網糧繭齋齋顧襯鑰網 顧糧製顧鑰顧鹹鏇齋窪 (鬱願網糧築糧鹽淵壓齋 ) | |||||||
N/A | - | - | 衊齋選壓膚網廠鏇積齋(淵繭鏇夢構蓋鹽繭淵築) = 顧積齋築膚鏇憲憲範鑰 簾構襯範餘艱廠繭憲鑰 (淵遞齋鹹願簾築衊膚醖, 25.8 ~ 26.5) | - | 1998-11-01 | ||
衊齋選壓膚網廠鏇積齋(淵繭鏇夢構蓋鹽繭淵築) = 簾鏇鬱糧觸糧網鹹廠築 簾構襯範餘艱廠繭憲鑰 (淵遞齋鹹願簾築衊膚醖, 107 ~ 115) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用